The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Clinical research
Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study)
Luis M. de la Fuente1, MD; Simon H. Stertzer2, MD; Julio Argentieri1, MD; Eduardo Peñaloza1, MD; Benjamin Koziner1, MD; Didier Rouy3, MD, PhD; Peter A. Altman3*, PhD
1. Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina; and Clinica Suizo Argentina, Buenos Aires, Argentina; 2. Stanford University Medical Center, Stanford, CA, USA; 3. BioCardia Inc., San Carlos, CA, USA
Aims: To assess the hypothesis that fluoroscopically-guided helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells (MNCs) in chronic p
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
heart failurecell therapycatheterstransplantation
Read next article
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial